Improving cancer outcomes with Radioligand Therapies

POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Radioligands offer improved efficacy and superior safety profiles versus platform chemotherapy agents and can provide patients and their families the very best possible outcomes.

Learn about POINT Biopharma

The Science of Radioligand Therapy

Although it may seem futuristic, radioligand therapy is a safe and proven treatment method for a variety of cancers.

First a scan is performed

Next the drug is administered

The drug then seeks out cancer

Learn about Radioligand Therapies

Our Treatment Pipeline

We are dedicated to expanding access to radiology therapies, making them applicable to more cancers, accessible to more people, and improving the lives of patients and their families. Here are the compounds we are currently developing:

Help improve the lives of patients and their families

We are hiring for clinical, manufacturing and business roles:

Careers at POINT Biopharma

News

POINT Biopharma Announces Initiation of Randomization for its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC

25 patient dosimetry and safety run-in met all pre-specified safety and efficacy criteria, Initiated patient enrollment in Canada with additional countries to begin enrolling in 4Q21.

Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV 01-α (Rosopatamab-225Ac) in combination with PNT2002 for Progressive mCRPC

Phase I/II investigator-Initiated Trial to be conducted at Weill Cornell Medicine, led by Principal Investigator, Dr. Scott T. Tagawa

NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Northstar Medical Radioisotopes and POINT Biopharma today announced the signing of a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).